Vanguard Portfolio Management
MNPR icon

Vanguard Portfolio Management’s Monopar Therapeutics MNPR Stock Holding History

Vanguard Portfolio Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.52M Buy
48,816
+2,829
+6% +$175K ﹤0.01% 2468
2026
Q1 		$2.52M Buy
+45,987
New +$2.78M ﹤0.01% 2533

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Portfolio Management's MNPR Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Monopar Therapeutics (MNPR) stake by 6.2% in Q2 2026, buying an estimated $175K and bringing the position to 48,816 shares worth $4.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Vanguard Portfolio Management first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Vanguard Portfolio Management held 48,816 shares of Monopar Therapeutics worth $4.52M as of Q2 2026.
  • Vanguard Portfolio Management bought 2,829 Monopar Therapeutics shares in Q2 2026, an estimated $175K.
  • Monopar Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2468 holding.
  • Vanguard Portfolio Management first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.